Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson’s disease patients

12Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

Abstract

Advances approaches in the treatment of Parkinson’s disease are needed. The study was aimed to evaluate the therapeutic value of the new dopamine receptor agonist pramipexole. The effects of pramipexole on serum exosomes were investigated, and the possible mechanisms of action of the drug were explored. Initially, 68 patients were included in the study, of whom 3 cases did not complete the study. The remaining 65 patients were administered pramipexole at increasing doses starting at 0.25 mg twice a day for the 1st week, and reaching 1.5 mg three times daily at the 8th week. The doses were tapered during the course of the following 4 weeks. The total scores of the motor examination of the unified Parkinson’s disease rating scale III (UPDRS III) and the total scores of the daily life activity in UPDRS II were compared before and after treatment. The relative expression amounts of α-synuclein in serum exosomes were then calculated by western blot analysis. Scores of UPDRS III and UPDRS II following treatment were significantly lower than the scores prior to treatment, and the difference was statistically significant (P<0.05). The relative expression of α-synuclein in serum exosomes was also found to be significantly lower after treatment (P<0.05). The relative expression of α-synuclein in the effective treatment group was significantly lower than that in the ineffective treatment group, and the difference was statistically significant (P<0.05). The relative expression of α-synuclein in serum exosomes was significantly correlated with treatment effects (P<0.05). In conclusion, pramipexole was effective and safe as a treatment for Parkinson’s disease. The therapeutic effect of pramipexole may be associated with its reducing effect on the relative expression of α-synuclein in serum exosomes.

References Powered by Scopus

Membrane vesicles as conveyors of immune responses

3346Citations
N/AReaders
Get full text

Parkinson's disease

1806Citations
N/AReaders
Get full text

Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles

1326Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Microglia as modulators of exosomal alpha-synuclein transmission

167Citations
N/AReaders
Get full text

Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke

58Citations
N/AReaders
Get full text

Role of exosomes in the pathogenesis of inflammation in Parkinson's disease

36Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Luo, H. T., Zhang, J. P., & Miao, F. (2016). Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson’s disease patients. Experimental and Therapeutic Medicine, 12(3), 1373–1376. https://doi.org/10.3892/etm.2016.3471

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 25

71%

Researcher 7

20%

Professor / Associate Prof. 2

6%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Neuroscience 11

39%

Biochemistry, Genetics and Molecular Bi... 8

29%

Pharmacology, Toxicology and Pharmaceut... 6

21%

Nursing and Health Professions 3

11%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free